Drug development

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

Retrieved on: 
Wednesday, March 2, 2022
Linda, MCV, Industry, Medicine, Exosome, Security (finance), Ownership, Principal, COVID-19, Â, U.S. Securities and Exchange Commission, III, Salem Veterans Affairs Medical Center, Doctor of Philosophy, Private Securities Litigation Reform Act, Vaccine, Organic acid, Instagram, Medical college, FDA, SAN, Veterans Health Administration, Therapy, Drug discovery, Drug development, Metabolism, Company, Development, Espresso, Daniel, Sanofi, Annual report, VA, Cardiology, Thrombosis, Internal medicine, Corporate social responsibility, RNA transfection, NASDAQ, Clinical, Bayer, Research, Twitter, Safety, VCU Medical Center, Drug, Goal, Faculty, Protein, Duchenne muscular dystrophy, Intellectual property, GLOBE, Pharmaceutical industry, Facebook

as Vice President of Clinical Development.

Key Points: 
  • as Vice President of Clinical Development.
  • On behalf of the entire Capricor team, we welcome Dr. Paulson to the Company, said Linda Marbn, Ph.D., Capricors Chief Executive Officer.
  • Dr. Paulson leverages approximately two decades of experience in drug development at several of the worlds leading pharmaceutical companies.
  • Prior to joining Capricor, he was Vice President of Development at Bayer AG, where he was the Group Head for Established Products and Corporate Social Responsibility.

Juva Life Launches Journal App, Offering Personal Health and Wellness Tracking for Cannabis Patients

Retrieved on: 
Wednesday, March 2, 2022
Pharmacy, Ageing, Patient, Â, Journal, Research, Biomarker, Privacy, News, Cannabis, Founder, CSE, Drug development, Legislation, Company, Inflammation, Patent, CEO, App, Physician, Health, THE, Face, Pharmacology, GLOBE, BOARD, Pharmaceutical industry, CBD

The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.

Key Points: 
  • The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.
  • Through the Journal App, cannabis consumers and anyone who uses hemp-based cannabidiol (CBD) products can track their symptoms, medication use and results.
  • Juva Life also has a pharmaceutical research and life sciences division, with a goal of identifying the mode of action behind cannabis anecdotal ability to regulate inflammation.
  • Juva is working to bring the Cannabis market face to face with the sectors next generation investment grade business model.

LEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease

Retrieved on: 
Wednesday, March 2, 2022
Risk, NEW, Weill Cornell Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, APOE, APOE4, Patient, Allele, Biomarker, Tau, Research, Genetics, Degenerative disease, Central nervous system, Food, Batten disease, Safety, Pathology, Peripheral nervous system, University, LinkedIn, Dementia, Therapy, Drug development, Fast Track, Cholesterol, AAV, Disease, CNS, Cerebrospinal fluid, University of California, San Diego Performance-Based Skills Assessment, Caregiver, APOE2, Brain, GLOBE, CSF, APOE3, Vaccine, Pharmaceutical industry, Medical imaging, Health insurance

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a deep and diverse pipeline of adeno-associated virus (AAV)-based gene therapy candidates for genetically defined cardiovascular and central nervous system (CNS) diseases, announced today positive initial expression and biomarker data from the low-dose cohort (cohort 1) of its ongoing Phase 1/2 clinical trial of LX1001. LX1001 is an AAV-based investigational gene therapy designed to deliver the protective apolipoprotein E2 (APOE2) gene into the CNS of APOE4 homozygous Alzheimer’s disease patients to halt or slow disease progression.

Key Points: 
  • LX1001 is an AAV-based investigational gene therapy designed to deliver the protective apolipoprotein E2 (APOE2) gene into the CNS of APOE4 homozygous Alzheimers disease patients to halt or slow disease progression.
  • LX1001 is the lead program in our Alzheimers disease gene therapy portfolio.
  • These encouraging data support our unique approach to target the genetics of Alzheimers disease with multiple gene therapy candidates, said R. Nolan Townsend, Chief Executive Officer of LEXEO.
  • LX1001 is an AAV-based gene therapy candidate designed as a one-time treatment delivering a protective APOE2 gene into the CNS for the treatment of APOE4-associated Alzheimers disease.

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Retrieved on: 
Wednesday, March 2, 2022
Failure, Alma College, Security (finance), COVID-19, Acquisition, ARM, Nephrology, Lung, U.S. Securities and Exchange Commission, Nasdaq, Hematology, Regenerative medicine, Marketing, Private Securities Litigation Reform Act, Alexion Pharmaceuticals, BP, FDA, Therapy, Drug development, SEC, Company, CEO, LTB4, Degenerative disease, Risk, TMA, Food, Eye, Annual report, Baxter International, EMA, Shire (pharmaceutical company), Baxter, Ravulizumab, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, HIV disease progression rates, Leukotriene, Leukotriene B4, Research, European Medicines Agency, Thrombotic microangiopathy, Biotechnology, Senior, Dow Corning, Intellectual property, Neurology, GLOBE, Pharmaceutical industry, Management, Baxalta, Akari, Rachel (given name), Finance, C5

Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition.

Key Points: 
  • Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition.
  • I am very pleased to be able to welcome Rachelle as CEO of Akari Therapeutics.
  • With her combined experience in C5 inhibition, immunology and rare diseases, Rachelle has a deep understanding of the potential of Akaris pipeline.
  • Before this appointment, Ms.Jacques served as Chief Executive Officer of Enzyvant Therapeutics Inc., acommercial-stage biotechnology company developing transformativeregenerativetherapies for rare diseases.

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

Retrieved on: 
Wednesday, March 2, 2022
Terminology, Private Securities Litigation Reform Act, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, Liver disease, SAN, Therapy, Drug development, Fatty liver disease, Degenerative disease, Institute of Liver and Biliary Sciences, COVID-19, NASH, Viral hepatitis, CHB, Nasdaq, GLOBE, Hepatitis, Pharmaceutical industry, Jacob Aligo

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.

Key Points: 
  • Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases.
  • Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH).
  • Any statements in this press release that are not historical facts may be considered forward-looking statements.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022

Retrieved on: 
Wednesday, March 2, 2022
Company, Cancer, Technology, CNS, Therapy, Patent, Patient, IO, CD137, Drug development, Investor, Pharmaceutical industry, Fine chemical

F-star Therapeutics, Inc.is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer.

Key Points: 
  • F-star Therapeutics, Inc.is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer.
  • F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy.
  • F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline.
  • The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.

Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress

Retrieved on: 
Wednesday, March 2, 2022
Cue, TCR, Patient, Immunotherapy, Research, Policy, Index (publishing), Financial condition report, Forward-looking statement, Papilloma, Toxic shock syndrome, Conversation, Food, Festival, Securities Exchange Act of 1934, Infection, Annual report, Board of directors, FDA, Drug development, Board, Head, COVID-19, Cancer, Patent, Securities Act of 1933, Marriott Marquis, Selective, Autoimmune disease, Neoplasm, Form 10-Q, Washington Marriott Marquis, Clinical trial, Tumor microenvironment, Risk, Drug Quality and Security Act, Analysis, APC, CUE, Result, Regulatory T cell, Nasdaq, Antibody, PMHC cellular microarray, MTD, GLOBE, Pharmaceutical industry, Vaccine

Data demonstrates favorable tolerability throughout a range of doses and anti-tumor activity as a monotherapy in late stage (HPV+ R/M HNSCC) patients.

Key Points: 
  • Data demonstrates favorable tolerability throughout a range of doses and anti-tumor activity as a monotherapy in late stage (HPV+ R/M HNSCC) patients.
  • The data provides support for proof of concept and de-risking of CUE-101 as well as subsequent programs and platform applications across the IL-2 based CUE-100 series.
  • The Festival of Biologics brings together pharma & biotech, academics and research institutes, together with their partners across the value chain.
  • This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in selective T cell modulation.

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, March 1, 2022
Employment, Patient, Hotel manager, Woman, ETS, Paclitaxel, Regulatory affairs, Breast cancer, Venetoclax, Castration, Chronic lymphocytic leukemia, SAN, Therapy, Drug development, Ewing's sarcoma, MCL, Company, Cancer, ROR1, Prostate cancer, Hematological Cancer Research Investment and Education Act, Nasdaq, CLL, Mantle cell lymphoma, GLOBE, Pharmaceutical industry

The award was made on March 1, 2022 under Oncternals 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company.

Key Points: 
  • The award was made on March 1, 2022 under Oncternals 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company.
  • The award consists of an option to purchase 12,500 shares of Oncternal common stock.
  • The award was approved by Oncternals compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and was granted as an inducement material to Ms. Gorak entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).
  • Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need.

Worldwide Allergy Immunotherapies Industry to 2027 - Featuring Allergy Therapeutics, DBV Technologies and Anergis Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, March 4, 2022
Health, Pharmaceutical, Allergy, Income, COVID-19, Disease, MITES, Inflammation, Drug development, Immune system, Awareness, Growth, Prevalence, Skin, Allergen, Vaccine, Animal, Sex industry

This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.

Key Points: 
  • This, coupled with advancements in the field of allergy diagnostics, is catalyzing the global allergy immunotherapies market growth.
  • What is the expected growth rate of the global allergy immunotherapies market during 2022- 2027?
  • What is the breakup of the global allergy immunotherapies market based on the allergy type?
  • 9. Who are the key players/companies in the global allergy immunotherapies market?

Cayuga Biotech Appoints Andrea Ashford-Hicks as Chief Executive Officer

Retrieved on: 
Thursday, March 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, NDA, Biotechnology, Trauma, Leadership, Patient, Industry, Science, College, GI, Doctor of Philosophy, University, FDA, Therapy, Bleeding, Survival, Drug development, College of Arts and Sciences, Wound healing, Senior, CNS, CEO, Burns, Merck Serono, Coagulopathy, Thrombosis, Gastrointestinal bleeding, United States Department of Defense aerospace vehicle designation, Commercialization, Hemostasis, Pharmaceutical industry, Pfizer, Agenus, Biology

Cayuga Biotech, an early-stage platform biotechnology company harnessing biomimetic polyphosphate to address severe bleeding and wound healing, today announced that Andrea Ashford-Hicks has been named the companys Chief Executive Officer (CEO).

Key Points: 
  • Cayuga Biotech, an early-stage platform biotechnology company harnessing biomimetic polyphosphate to address severe bleeding and wound healing, today announced that Andrea Ashford-Hicks has been named the companys Chief Executive Officer (CEO).
  • Ms. Ashford-Hicks, who brings more than 20 years of industry experience, will succeed Damien Kudela, PhD, the inventor of lead candidate CAY001 and co-founder of Cayuga Biotech, who will assume the role of Chief Scientific Officer.
  • We are thrilled to welcome Andrea to our team which marks an important milestone for Cayuga, said Dr. Kudela, co-founder of Cayuga Biotech.
  • Cayuga Biotech is an early-stage platform biotechnology company harnessing biomimetic polyphosphate to address severe bleeding and wound healing.